Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Gut Microbiota in Parkinson's Disease
NCT03958708Phase 2Unknown
- Sponsor
- Taipei Medical University Shuang Ho Hospital
- Start
- May 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in Parkinson's disease (PD), sponsored by Taipei Medical University Shuang Ho Hospital. Status: unknown.
02
Drugs
rifaximin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03958708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03958708.